https://wikem.org/w/index.php?action=history&feed=atom&title=Ivabradine 2026-04-21T09:34:32Z Revision history for this page on the wiki MediaWiki 1.38.2 https://wikem.org/w/index.php?title=Ivabradine&diff=372220&oldid=prev 2023-12-30T15:45:09Z

<p>Created page with &quot;==Administration== *Type: Miscellaneous Cardiovascular Agents *Dosage Forms: Oral solution (5mg/mL) and Tablet (5 mg, 7.5 mg) *Routes of Administration: PO *Common Trade Names: Corlanor, Procoralan ==Adult Dosing== *2.5mg to 7.5mg twice daily ==Pediatric Dosing== *Greater than 40kg: 2.5mg to 7.5mg twice daily *Less than 40kg: Starting dose is 0.05 mg/kg twice daily **6 months to 1 year maximum dose - 0.2mg/kg twice daily **1&lt; year maximum dose - 0.3mg/kg up to 7.5mg tw...&quot;</p> <p><b>New page</b></p><div>==Administration==<br /> *Type: Miscellaneous Cardiovascular Agents<br /> *Dosage Forms: Oral solution (5mg/mL) and Tablet (5 mg, 7.5 mg)<br /> *Routes of Administration: PO<br /> *Common Trade Names: Corlanor, Procoralan<br /> <br /> ==Adult Dosing==<br /> *2.5mg to 7.5mg twice daily<br /> <br /> ==Pediatric Dosing==<br /> *Greater than 40kg: 2.5mg to 7.5mg twice daily<br /> *Less than 40kg: Starting dose is 0.05 mg/kg twice daily<br /> **6 months to 1 year maximum dose - 0.2mg/kg twice daily<br /> **1&lt; year maximum dose - 0.3mg/kg up to 7.5mg twice daily<br /> <br /> ==Special Populations==<br /> ===[[Drug pregnancy categories|Pregnancy Rating]]===<br /> *Benefit should outweigh risk; monitor for congestive heart failure destabilization, especially during the first trimester; monitor for preterm birth during the third trimester in pregnant women with chronic heart failure<br /> <br /> ===Lactation risk===<br /> *Use is not recommended. The effects in the nursing infant are unknown.<br /> <br /> ===Renal Dosing===<br /> *No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min. No data are available for patients with creatinine clearance below 15 mL/min.<br /> <br /> <br /> ===Hepatic Dosing===<br /> *No dose adjustment is required in patients with mild or moderate hepatic impairment. Corlanor is<br /> contraindicated in patients with severe hepatic impairment.<br /> <br /> ==Indications== <br /> Reduction of angina and risk of hospitalization for patients with:<br /> *Stable symptomatic chronic heart failure with reduced left ventricular ejection fraction<br /> *Stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older<br /> <br /> ==Contraindications==<br /> *Allergy to class/drug<br /> *Acute decompensated heart failure <br /> *Clinically significant hypotension <br /> *Sick sinus syndrome, sinoatrial block or 3rd degree AV block, unless a functioning demand pacemaker is present <br /> *Severe hepatic impairment <br /> *Heart rate maintained exclusively by the pacemaker <br /> *In combination with strong cytochrome CYP3A4 inhibitors <br /> <br /> ==Adverse Reactions==<br /> ===Common===<br /> *Bradycardia<br /> *Hypertension<br /> *Atrial fibrillation <br /> *Luminous phenomena<br /> <br /> ==Pharmacology==<br /> *Half-life: 6 hours<br /> *Metabolism: Liver extensively; CYP3A4<br /> *Excretion: ~50% Urine (~4% oral dose unchanged); ~50% Feces<br /> <br /> ==Mechanism of Action==<br /> Hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker; Pacemaker current I(f) inhibitor<br /> <br /> <br /> ==See Also==<br /> [[Congestive heart failure]]<br /> <br /> ==References==<br /> FDA Corlanor Prescribing Information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209964lbl.pdf<br /> &lt;references/&gt;<br /> <br /> [[Category:Pharmacology]]</div>

Parkerw02